CRISPR-Cas9 Nanoparticle Delivery for ANGPTL3 Gene Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for developing safe and effective therapies for treating ANGPTL3-related diseases and disorders, which are associated with lipid metabolism abnormalities.
Innovation Solution
The method involves administering nanoparticles complexed with a guide RNA (gRNA) targeting the ANGPTL3 gene and a nucleic acid encoding an RNA-guided endonuclease, such as Cas9, to reduce ANGPTL3 expression and treat related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If CRISPR-Cas9 genome editing is used to target ANGPTL3 gene, then ANGPTL3 expression is reduced effectively, but delivery safety and efficiency to liver tissue needs improvement
Solution Approach 1:
Lipid nanoparticles serve as an intermediary delivery vehicle that protects CRISPR-Cas9 components during transport and enables targeted delivery to liver tissue. The nanoparticle formulation includes ionizable lipids, helper lipids, and PEGylated lipids that facilitate cellular uptake while minimizing off-target effects and immune responses.
Solution Approach 2:
The patent optimizes multiple parameters including nanoparticle size (20-200 nm), zeta potential, lipid composition ratios, and Cas9-to-gRNA ratios to achieve maximum liver targeting efficiency while minimizing toxicity. Dose optimization ranges from 0.1 to 10 mg/kg of Cas9 protein to balance efficacy and safety.
2Duration of action of stationary object
If repeated administrations are given to maintain therapeutic effect, then treatment durability is improved, but cumulative toxicity risk increases
Solution Approach 1:
The patent establishes optimized dosing intervals (every 3-12 months) based on the half-life of CRISPR-Cas9 components in the body. This periodic administration schedule maintains therapeutic ANGPTL3 suppression while allowing sufficient time for component clearance to minimize cumulative toxicity.
Solution Approach 2:
The patent incorporates monitoring of ANGPTL3 protein levels, lipid profiles, and safety biomarkers to guide repeat dosing decisions. Therapeutic effect feedback determines whether additional dosing is needed, while safety feedback prevents administration if toxicity thresholds are approached.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces ANGPTL3 protein expression and non-high-density lipoprotein (non-HDL) lipid levels, thereby treating ANGPTL3-related diseases and disorders.
Implementation Method 1
Type II CRISPR-Cas-based systems have been used for genome editing, and require a Cas polypeptide or variant thereof guided by a customizable guide RNA (gRNA) for programmable DNA targeting
Implementation Method 2
The targeting of DNA using the RNA-guided, DNA-targeting principle of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas (CRISPR associated) systems
Implementation Method 3
administering to a subject (e.g., primate subject) a plurality of nanoparticles complexed with (a) a guide RNA (gRNA) targeting ANGPTL3 gene
Implementation Method 4
ANGPTL3 dually inhibits the catalytic activities of lipoprotein lipase (LPL), which catalyzes the hydrolysis of triglycerides
Implementation Method 5
ANGPTL3 dually inhibits the catalytic activities of lipoprotein lipase (LPL), which catalyzes the hydrolysis of triglycerides, and of endothelial lipase (EL), which hydrolyzes high density lipoprotein (HDL) phospholipids
Data Source
AI summary
The present disclosure relates to methods, compositions and kits for treating conditions that are related with angiopoietin-like 3 (ANGPTL3) by gene editing.